rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2011-65rsp-349Research ArticleСтатьиArticlesПОДАГРА У МОЛОДЫХ ЖЕНЩИН, ИНДУЦИРОВАННАЯ ФУРОСЕМИДОМLivedoid vasculopathy: experience in using rituximabМуравьевЮ. В.MuravyevYuri Vladimirovichmurawyu@mail.ruAlekseyevaA VAlekseyevaA V-MuravyevaN VMuravyevaN V-201115082011494№4 (2011)7577Copyright © Муравьев Ю.В., Alekseyeva A.V., Muravyeva N.V., 20112011Муравьев Ю.В., Alekseyeva A.V., Muravyeva N.V.Muravyev Y.V., Alekseyeva A.V., Muravyeva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/349References<div><p>Jorizzo J.L. Livedoid vasculopathy: what is it? Arch Dermatol 1998;134:491-3.</p><p>Feldaker M., Hines E.A. Jr., Kierland R.R. Livedo reticularis with summer ulcerations. AMA Arch Derm 1955;72:31-42.</p><p>Bard J.W., Winkelmann R.K. Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967;96:489-99.</p><p>Hairston B.R., Davis M.D., Pittelkow M.R., Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol 2006;142:1413-8.</p><p>Kavala M., Kocaturk E., Zindanci I. et al. A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin. J Dermatolog Treat 2008; 19:121-3.</p><p>Deng A., Gocke C.D., Hess J. et al. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 2006; 142:1466-9</p><p>Antunes J., Filipe P., Andre M. et al. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy. Acta Derm Venereol 2010;90:91-2.</p><p>Gotlib J., Kohler S., Reicherter P. et al. Heterozygous prothrombin G20210A gene mutation in a patient with livedoid vasculitis. Arch Dermatol 2003;139:1081-3.</p><p>Boyvat A., Kundakci N., Babikir M.O., Gurgey E. Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol 2000;143:840-2.</p><p>Baccard M., Vignon-Pennamen M.D., Janier M. et al. Livedo vasculitis with protein C system deficiency. Arch Dermatol 1992; 128:1410-1.</p><p>Meiss F., Marsch W.C., Fischer M. Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences. Eur J Dermatol 2006;16:159-62.</p><p>Gibson G.E., Li H., Pittelkow M.R. Homocysteinemia and livedoid vasculitis. J Am Acad Dermatol 1999;40:279-81.</p><p>Pizzo S.V., Murray J.C., Gonias S.L. Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator. Arch Pathol Lab Med 1986;110:517-9.</p><p>Papi M., Didona B., De Pita O. et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol 1998;134:447-52.</p><p>Coleridge Smith P.D., Thomas P., Scurr J.H., Dormandy J.A. Causes of venous ulceration: a new hypothesis. Br Med J (Clin Res Ed) 1988;296:1726-7.</p><p>Marzano A.V., Vanotti M., Alessi E. Widespread livedoid vasculopathy. Acta Derm Venereol 2003;83:457-60.</p><p>Toth C., Trotter M., Clark A., Zochodne D. Mononeuropathy multiplex in association with livedoid vasculitis. Muscle Nerve 2003; 28:634-9.</p><p>Ackerman A.B., Chongchitnant N., Sanchez J. Histologic diagnosis of inflammatory skin diseases: an algorithmic method based on pattern analysis. 2nd ed. Baltimore, Md: Williams & Wilkins, 1997. Kern A.B. Atrophie blanche. Report of two patients treated with aspirin and dipyridamole. J Am Acad Dermatol 1982;6:1048-53.</p><p>Sams W.M. Livedo vasculitis. Therapy with pentoxifylline. Arch Dermatol 1988;124:684-7.</p><p>Hairston B.R., Davis M.D., Gibson L.E., Drage L.A. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol 2003;139:987-90.</p><p>Davis M.D., Wysokinski W.E. Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin. J Am Acad Dermatol 2008;58:512-5.</p><p>Yang C.H., Ho H.C., Chan Y.S. et al. Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen. Br J Dermatol 2003;149:647-52.</p><p>Juan W.H., Chan Y.S., Lee J.C. et al. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy. Br J Dermatol 2006;154:251-5.</p><p>Frances C., Barete S. Difficult management of livedoid vasculopathy. Arch Dermatol 2004; 140:1011.</p><p>Amital H., Levy Y., Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol 2000;18:404-6.</p><p>Kreuter A., Gambichler T., Breuckmann F. et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 2004;51:574-9.</p><p>Zeni P., Finger E., Scheinberg M.A. Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy. Ann Rheum Dis 2008;67:1055-6.</p><p>Song E.J., Kang J.W., Kim J.H. et al. Successful treatment of refractory livedoid vasculitis with rituximab and cyclophosphamide. Korean J Med 2010;78:527-30.</p><p>Bennett D., Ohanian M., Cable C. Rituximab in severe skin diseases: target, disease, and dose. Clin Pharmacol Adv Appl 2010; 2:135-41.</p><p>Simka M. Cellular and molecular mechanisms of venous leg ulcers development - the «puzzle» theory. Int Angiol 2010;29:1-19.</p><p>Zamboni P. The Big Idea: Iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006; 99:589-93</p></div><br /><div><p>Jorizzo J.L. Livedoid vasculopathy: what is it? Arch Dermatol 1998;134:491-3.</p><p>Feldaker M., Hines E.A. Jr., Kierland R.R. Livedo reticularis with summer ulcerations. AMA Arch Derm 1955;72:31-42.</p><p>Bard J.W., Winkelmann R.K. Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967;96:489-99.</p><p>Hairston B.R., Davis M.D., Pittelkow M.R., Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol 2006;142:1413-8.</p><p>Kavala M., Kocaturk E., Zindanci I. et al. A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin. J Dermatolog Treat 2008; 19:121-3.</p><p>Deng A., Gocke C.D., Hess J. et al. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 2006; 142:1466-9</p><p>Antunes J., Filipe P., Andre M. et al. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy. Acta Derm Venereol 2010;90:91-2.</p><p>Gotlib J., Kohler S., Reicherter P. et al. Heterozygous prothrombin G20210A gene mutation in a patient with livedoid vasculitis. Arch Dermatol 2003;139:1081-3.</p><p>Boyvat A., Kundakci N., Babikir M.O., Gurgey E. Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol 2000;143:840-2.</p><p>Baccard M., Vignon-Pennamen M.D., Janier M. et al. Livedo vasculitis with protein C system deficiency. Arch Dermatol 1992; 128:1410-1.</p><p>Meiss F., Marsch W.C., Fischer M. Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences. Eur J Dermatol 2006;16:159-62.</p><p>Gibson G.E., Li H., Pittelkow M.R. Homocysteinemia and livedoid vasculitis. J Am Acad Dermatol 1999;40:279-81.</p><p>Pizzo S.V., Murray J.C., Gonias S.L. Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator. Arch Pathol Lab Med 1986;110:517-9.</p><p>Papi M., Didona B., De Pita O. et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol 1998;134:447-52.</p><p>Coleridge Smith P.D., Thomas P., Scurr J.H., Dormandy J.A. Causes of venous ulceration: a new hypothesis. Br Med J (Clin Res Ed) 1988;296:1726-7.</p><p>Marzano A.V., Vanotti M., Alessi E. Widespread livedoid vasculopathy. Acta Derm Venereol 2003;83:457-60.</p><p>Toth C., Trotter M., Clark A., Zochodne D. Mononeuropathy multiplex in association with livedoid vasculitis. Muscle Nerve 2003; 28:634-9.</p><p>Ackerman A.B., Chongchitnant N., Sanchez J. Histologic diagnosis of inflammatory skin diseases: an algorithmic method based on pattern analysis. 2nd ed. Baltimore, Md: Williams & Wilkins, 1997. Kern A.B. Atrophie blanche. Report of two patients treated with aspirin and dipyridamole. J Am Acad Dermatol 1982;6:1048-53.</p><p>Sams W.M. Livedo vasculitis. Therapy with pentoxifylline. Arch Dermatol 1988;124:684-7.</p><p>Hairston B.R., Davis M.D., Gibson L.E., Drage L.A. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol 2003;139:987-90.</p><p>Davis M.D., Wysokinski W.E. Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin. J Am Acad Dermatol 2008;58:512-5.</p><p>Yang C.H., Ho H.C., Chan Y.S. et al. Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen. Br J Dermatol 2003;149:647-52.</p><p>Juan W.H., Chan Y.S., Lee J.C. et al. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy. Br J Dermatol 2006;154:251-5.</p><p>Frances C., Barete S. Difficult management of livedoid vasculopathy. Arch Dermatol 2004; 140:1011.</p><p>Amital H., Levy Y., Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol 2000;18:404-6.</p><p>Kreuter A., Gambichler T., Breuckmann F. et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 2004;51:574-9.</p><p>Zeni P., Finger E., Scheinberg M.A. Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy. Ann Rheum Dis 2008;67:1055-6.</p><p>Song E.J., Kang J.W., Kim J.H. et al. Successful treatment of refractory livedoid vasculitis with rituximab and cyclophosphamide. Korean J Med 2010;78:527-30.</p><p>Bennett D., Ohanian M., Cable C. Rituximab in severe skin diseases: target, disease, and dose. Clin Pharmacol Adv Appl 2010; 2:135-41.</p><p>Simka M. Cellular and molecular mechanisms of venous leg ulcers development - the «puzzle» theory. Int Angiol 2010;29:1-19.</p><p>Zamboni P. The Big Idea: Iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006; 99:589-93</p></div><br />
The authors declare that there are no conflicts of interest present.